Biological subtypes of breast cancer: Current concepts and implications for recurrence patterns

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 4, 2013, Pages 312-321

  Cadoo, K A ^a   Fornier, M N ^a   Morris, P G ^a,b,c  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b BEAUMONT HOSPITAL   (Ireland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Biological markers; Breast neoplasms; Recurrence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; HISTOPATHOLOGY; HUMAN; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

EID: 84891622107     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Cancer Facts & Figures 2012 [Internet]. Available at http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/ document/acspc-031941.pdf [cited 2013, Mar 2].
2. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov 2012;11:479-97.
3. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000;406:747-52.
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74. (Pubitemid 32878711)
5. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. New Engl J Med 2009;360:790-800.
6. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7:96.
7. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100-10.
8. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5-23.
9. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34. (Pubitemid 46698581)
10. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-85. (Pubitemid 41170290)
11. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nat Rev Cancer 2007;7:545-53. (Pubitemid 46985399)
12. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104-7.
13. Nadji M, Gomez-Fernandez C, Ganjei-Azar P, Morales AR. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers. Am J Clin Pathol 2005;123:21-7. (Pubitemid 40066168)
14. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-6. (Pubitemid 30212316)
15. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN. Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003;78:105-18. (Pubitemid 36223023)
16. Li CI, Daling JR, Malone KE. Incidence of invasive breast cancer by hormone receptor status from 1992 to 1998. J Clin Biol 2003;21:28-34.
17. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Canc Res Treat 2002;76:27-36. (Pubitemid 35178626)
18. Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev 2002;11:601-7. (Pubitemid 34760817)
19. Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Canc Treat Rev 2012;38:698-707.
20. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996;14:2738-46. (Pubitemid 26329660)
21. Anderson WF, Chen BE, Jatoi I, Rosenberg PS. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer. Breast Cancer Res Treatment 2006;100:121-6.
22. Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 2011;29:2301-4.
23. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
24. Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ et al. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol 2010;66:507-16.
25. Aristei C, Leonardi C, Stracci F, Palumbo I, Luini A, Viale G et al. Risk factors for relapse after conservative treatment in T1-T2 breast cancer with one to three positive axillary nodes: results of an observational study. Ann Oncol 2011;22.842-7.
26. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005;103:2241-51. (Pubitemid 40686567)
27. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-9. (Pubitemid 46606386)
28. Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:435-44.
29. Sparano JA, Wang M, Zhao F, Stearns V, Martino S, Ligibel JA et al. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J J Natl Cancer Inst 2012;104:406-14.
30. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26. (Pubitemid 40051905)
31. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-34. (Pubitemid 46622311)
32. Demicheli R, Ardoino I, Boracchi P, Coradini D, Agresti R, Ferraris C et al. Recurrence and mortality according to estrogen receptor status for breast cancer patients undergoing conservative surgery. Ipsilateral breast tumour recurrence dynamics provides clues for tumour biology within the residual breast. BMC Cancer 2010;10:656.
33. Shah C, Wilkinson JB, Lyden M, Beitsch P, Vicini FA. Predictors of local recurrence following accelerated partial breast irradiation: a pooled analysis. Int J Radiat Oncol Biol Phys 2012,82:e825-30.
34. Panet-Raymond V, Truong PT, Alexander C, Lesperance M, McDonald RE, Watson PH. Clinicopathologic factors of the recurrent tumor predict outcome in patients with ipsilateral breast tumor recurrence. Cancer 2011;117:2035-43.
35. Lee SJ, Park S, Ahn HK, Yi JH, Cho EY, Sun JM et al. Implications of bone-only metastases in breast cancer: favorable preference with excellent outcomes of hormone receptor positive breast cancer. Cancer Res Treat 2011;43:89-95.
36. Gupta GP, Minn AJ, Kang Y, Siegel PM, Serganova I, Cordón-Cardo C et al. Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol 2005;70:149-58. (Pubitemid 44124866)
37. Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009;16:67-78.
38. Li CI, Anderson BO, Daling JR, Moe RE. Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA 2003;289:1421-4. (Pubitemid 37430310)
39. Rakha EA, El-Sayed ME, Powe DG, Green AR, Habashy H, Grainge MJ et al. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008;44:73-83. (Pubitemid 350256943)
40. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008;26:3006-14.
41. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-56.
42. Iorfida M, Maiorano E, Orvieto E, Maisonneuve P, Bottiglieri L, Rotmensz N et al. Invasive lobular breast cancer: subtypes and outcome. Breast Cancer Res Treat 2012;133:713-23.
43. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005,93:1046-52. (Pubitemid 41548400)
44. Mersin H, Yildirim E, Gulben K, Berberoglu U. Is invasive lobular carcinoma different from invasive ductal carcinoma? Eur J Surg Oncol 2003;29:390-5. (Pubitemid 36675699)
45. Fortunato L, Mascaro A, Poccia I, Andrich R, Amini M, Costarelli L et al. Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? analysis of an institutional database over a 10-year period. Ann Surg Oncol 2012;19:1107-14.
46. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005;23:41-8. (Pubitemid 41702621)
47. Moran MS, Yang Q, Haffty BG. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology. Breast J 2009;15:571-8.
48. Anwar IF, Down SK, Rizvi S, Farooq N, Burger A, Morgan et al. Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease? Int J Surg 2010;8:346-52.
49. Hussien M, Lioe TF, Finnegan J, Spence RA. Surgical treatment for invasive lobular carcinoma of the breast. Breast 2003;12:23-35. (Pubitemid 36395483)
50. Ferlicot S, Vincent-Salomon A, Médioni J, Genin P, Rosty C, Sigal-Zafrani B et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004;40:336-41. (Pubitemid 38121269)
51. McLemore EC, Pockaj BA, Reynolds C, Gray RJ, Hernandez JL, Grant CS et al. Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. Ann Surg Oncol 2005;12:886-94. (Pubitemid 41504221)
52. Rakha EA, Patel A, Powe DG, Benhasouna A, Green AR, Lambros MB et al. Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast. Am J Surg Pathol 2010;34:1472-9.
53. Bertucci F, Orsetti B, Nègre V, Finetti P, Rougé C, Ahomadegbe JC et al. Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008;27:5359-72.
54. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 2001;344:783-92. (Pubitemid 32222155)
55. Hudis CA. Trastuzumab-mechanism of action and use in clinical practice. New Engl J Med 2007;357:39-51. (Pubitemid 47026733)
56. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 2009;14:320-68.
57. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN et al. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 2012;118.5463-72.
58. Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner et al. Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer 2003;98:2547-53. (Pubitemid 37509516)
59. Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP et al. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 2013;22:525-31.
60. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E et al. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005;58:611-6. (Pubitemid 40814021)
61. Sjogren S, Inganas M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Onco 1998;16:462-9. (Pubitemid 28135587)
62. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353.1673-84.
63. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New Engl J Med 2012;367:1783-91.
64. Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treatment 2012;133:831-41.
65. Miller AR, Brandao G, Prihoda TJ, Hill C, Cruz AB, Jr., Yeh IT. Positive margins following surgical resection of breast carcinoma: analysis of pathologic correlates. J Surg Oncol 2004;86:134-40. (Pubitemid 38720763)
66. Atalay C, Irkkan C. Predictive factors for residual disease in re-excision specimens after breast-conserving surgery. Breast J 2012;18:339-44.
67. Bendell JC, Domchek SM, Burstein HJ, Harris L, Younger J, Kuter et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7. (Pubitemid 36676250)
68. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638-45.
69. Gori S, Rimondini S, De Angelis V, Colozza M, Bisagni G, Moretti G et al. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007;12:766-73. (Pubitemid 47328220)
70. Vern-Gross TZ, Lawrence JA, Case LD, McMullen KP, Bourland JD, Metheny-Barlow LJ et al. Breast cancer subtype affects patterns of failure of brain metastases after treatment with stereotactic radiosurgery. J Neurooncol 2012;110:381-8.
71. Tseng LM, Hsu NC, Chen SC, Lu YS, Lin CH, Chang D et al. Distant metastasis in triple-negative breast cancer. Neoplasma 2013;60:290-4.
72. Morris PG, Murphy CG, Mallam D, Accordino M, Patil S, Howard J et al. Limited overall survival in patients with brain metastases from triple negative breast cancer. Breast J 2012;18:345-50.
73. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-84. (Pubitemid 47257667)
74. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34. (Pubitemid 47219710)
75. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109:1721-8. (Pubitemid 46668532)
76. Dogan BE, Turnbull LW. Imaging of triple-negative breast cancer. Ann Oncol 2012;23(Suppl 6):vi23-9.
77. Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treatment 2009;115:423-8.
78. Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J 2008;14:456-63.
79. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-81.
80. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
81. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
82. Gabos Z, Thoms J, Ghosh S, Hanson J, Deschenes J, Sabri S et al. The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 2010;124:187-94.
83. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol 2011;29:2852-8.
84. Chen X, Yu X, Chen J, Yang Z, Shao Z, Zhang Z et al. Radiotherapy can improve the disease-free survival rate in triple-negative breast cancer patients with t1-t2 disease and one to three positive lymph nodes after mastectomy. Oncologist 2013;18:141-7.
85. Ovcaricek T, Frkovic SG, Matos E, Mozina B, Borstnar S. Triple negative breast cancer - prognostic factors and survival. Radiology and oncology 2011;45:46-52.
86. Konigsberg R, Pfeiler G, Klement T, Hammerschmid N, Brunner A, Zeillinger R et al. Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (>/=65) patients. Eur J Cancer 2012;48:2962-8.
87. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-81.
88. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004;22:2865-72. (Pubitemid 41079905)
89. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. New Engl J Med 2010;363:1938-48.